Name | Progabide |
Description | Progabide (SL 76002) is an agonist of the gamma-aminobutyric acid receptor. |
In vivo | Progabide ( 50, 100 and 200 mg/kg) given IP to male Wistar rats enhance the plasma corticosterone levels by 244, 365, and 476% respectively (t=6.44 to12.55, p<0.01). Progabide (10 mg/kg) fails to change the concentration of corticosterone in plasma (t=0.76, N.S.). The increased plasma corticosterone level induced by administration of 200 mg/kg Progabide is evident 30 (t=2.625, p<0.05), 60 (t=13.13, p<0.001) and 120 min (t=4.07, p<0.01) after drug injection, but returns to the control value 240 min after drug injection (t=0.86, N.S.). Compare with the corresponding control, The greatest corticosterone rise is reached 60 min following the administration of Progabide[1]. |
Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 225 mg/mL (672.1 mM), Sonication is recommended.
|
Keywords | SL-76002 | SL76002 | Progabide | GABAReceptor | GABA receptor | GABA Receptor |
Inhibitors Related | Valproic acid sodium salt | DL-Menthol | p-Hydroxybenzaldehyde | Penicillin G sodium salt | Valproic Acid | Halothane | Chlorothymol | Piperazine citrate | Riluzole | Gabapentin | (-)-α-Pinene | Methionine |
Related Compound Libraries | Pain-Related Compound Library | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Antidepressant Compound Library | Membrane Protein-targeted Compound Library | Neurotransmitter Receptor Compound Library | CNS-Penetrant Compound Library | Neuroprotective Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Ion Channel Targeted Library | Anti-Cancer Compound Library |